IP Group (LON:IPO) Posts Earnings Results

Key Points

• IP Group’s NAV per share increased 3.2% to 114p by June 30 and about 117p by September 11, while gross cash reached approximately £239 million.
• Cash realizations totaled £69 million in the first half and about £86 million year to date, putting the company at £154 million toward its £250 million realization target by the end of 2027.
• Despite a “Buy” consensus and a GBX 114.50 target price, shares trade at roughly a 40% discount to NAV; management is considering shareholder returns, with around £50 million available, but has not decided on timing or form.

IP Group (LON:IPO - Get Free Report) posted its earnings results on Tuesday. The company reported GBX 3.53 earnings per share for the quarter, Digital Look Earnings reports. IP Group had a return on equity of 7.14% and a net margin of 148.78%.

Here are the key takeaways from IP Group's conference call:

• NAV per share rose 3.2% to 114p at June 30 and approximately 117p by September 11, while gross cash reached about £239 million. Portfolio companies also raised more than £500 million from third parties, providing external validation of their progress.
• Pfizer’s obesity programs continued to de-risk, with the royalty asset’s carrying value increasing by £27 million to roughly £153 million after the amylin combination entered Phase IIb. Berobenatide Phase III recruitment is reportedly close to completion, supporting a potential 2028 launch, although clinical, regulatory and commercial risks remain.
• Cash realizations were strong at £69 million in the first half and approximately £86 million year to date, taking cumulative proceeds since the start of 2025 to £154 million. Management remains confident in reaching its £250 million realization target by the end of 2027.
• Oxford Nanopore reported 12% constant-currency revenue growth, a 400-basis-point gross-margin improvement and an adjusted EBITDA loss that more than halved. It remains on track for EBIT break-even in 2027 and positive free cash flow in 2028, supported by a new cross-licensing agreement with $35 million of committed revenue plus royalties.
• Management acknowledged that the shares continue to trade at roughly a 40% discount to NAV and said reducing the gap will require sustained NAV growth, more realizations and shareholder-focused capital allocation. Around £50 million is available for potential shareholder returns, but the timing and form of any action have not been decided.

IP Group Trading Up 4.3%

Shares of IPO stock opened at GBX 68.50 on Tuesday. The firm has a 50 day moving average price of GBX 67.69 and a two-hundred day moving average price of GBX 62.94. The company has a quick ratio of 8.59, a current ratio of 0.16 and a debt-to-equity ratio of 12.28. The company has a market capitalization of £605.16 million, a PE ratio of 9.65 and a beta of 1.27. IP Group has a 12-month low of GBX 48 and a 12-month high of GBX 75.

Analyst Ratings Changes

Separately, Berenberg Bank reaffirmed a "buy" rating and set a GBX 119 price objective on shares of IP Group in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of GBX 114.50.

Insider Activity

In other news, insider David Baynes purchased 26,368 shares of IP Group stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of GBX 68 per share, for a total transaction of £17,930.24. Also, insider Michael Queen acquired 200,000 shares of the stock in a transaction on Tuesday, August 4th. The shares were purchased at an average price of GBX 66 per share, for a total transaction of £132,000. Over the last quarter, insiders have bought 271,368 shares of company stock valued at $18,053,024. 1.57% of the stock is owned by insiders.

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach.